Lilly's next-gen weight loss drug more than doubled Novo Nordisk's in trial
Retatrutide lowered A1C, a blood sugar measure, by 2.2% versus 1.8% for Ozempic, but 7.9% on the 12 mg dose stopped treatment over side effects
Ozempic's rival, retatrutide, is a more potent weight-loss drug developed by Eli Lilly. In a clinical trial, retatrutide users lost roughly twice as much weight compared to those taking Ozempic. The trial results showed that Ozempic users on the highest dose lost an average of 21 pounds over a year and a half, while retatrutide users lost an average of 44 to 47 pounds during the same period.
Retatrutide has the potential to change the treatment paradigm for type 2 diabetes, obesity, and related cardiometabolic conditions. The drug is still in clinical development and has not received FDA approval yet. Some peptide sellers are illegally selling a knock-off version of retatrutide, which is referred to as 'reta'. The FDA is expected to review and approve retatrutide in early 2027, potentially making it available for obesity, sleep apnea, and knee osteoarthritis.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
